Actavis appointed Jonathon Kellerman as executive vice president, global chief compliance officer.
GI & Endoscopy
A new study, published in Colorectal Disease, examines histopathology changes after non-ablative radiofrequency to smooth muscle as delivered by Stretta therapy for gastroesophageal reflux disease and Secca therapy for fecal incontinence.
The American Gastroenterological Association Center for GI Innovation and Technology's STAR Registry has enrolled its first two patients.
Medicare often set trends for commercial payers, and Highmark has determined it will opt for Medicare's stance and lift restrictions on colorectal cancer screening drugs, according to a Pittsburgh Business Times report.
TiGenix submitted the required documentation for a Special Protocol Assessment of its pivotal Phase III trial design for Cx601 to the U.S. Food and Drug Administration.
Advertisement
The U.S. Food and Drug Administration approved Viekira Pak to treat patients with chronic hepatitis C virus, including those with cirrhosis.
Alphonso Belsito, MD, has joined the Gastroenterology Associates of Manatee in Bradenton, Fla., according to a Bradenton Herald report.
With each New Year comes a fresh batch of CPT updates. The three GI sister societies have released a report on 2015 coding updates for gastroenterologists to know. Here are 17 colonoscopy coding updates to know.
Actavis President and CEO Brent Saunders will continue to lead the firm after its acquisition by Allergan in the second quarter of next year, according to a RTT News report.
The U. S. Food and Drug Administration approved lanreotide (Somatuline Depot Injection, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.